Dear Fellow Stakeholders,
For Biogen Idec, the past year was one of genuine progress and a clear demonstration of our enduring commitment to the patients we serve. During that time, we unveiled important therapeutic advances including the introduction of new treatments for those suffering from multiple sclerosis (MS) and hemophilia; through business and academic relationships we expanded our pipeline with product candidates for diseases with few or no treatment options such as Alzheimer’s disease, sickle cell anemia and beta thalassemia; and we deepened our neurology research to map pathways involved in progressive forms of MS, neuropathic pain and amyothrophic lateral sclerosis (ALS).
It also was a year where we strengthened our commitment to corporate citizenship and environmental sustainability. From rolling out new environmental goals, extending our philanthropic and education initiatives globally, investing in our employees and expanding our engagement with organizations that support patients in need, Biogen Idec continued to shape the meaning of good corporate citizenship, both as a leading biotech and as an expanding enterprise.
Corporate citizenship is incorporated deeply into our day-today business activities and is a cultural imperative across the organization. Our efforts increasingly are embraced by our employees and recognized by respected external entities. In the past year:
- Biogen Idec earned a place on the prestigious Dow Jones Sustainability World Index, becoming the first and only U.S.-based biotechnology company to make the list.
- We were named to the Dow Jones Sustainability Index North America for the fourth consecutive year, one of only three biotech companies included — recognition that speaks to our high level of performance on both environmental and social measures.
- We earned the top Carbon Disclosure Score for the biotech sector in the Carbon Disclosure Project Annual Investor Survey, demonstrating both a high degree of transparency regarding our carbon footprint and our continued focus on being a more environmentally sustainable organization globally. (And having reached our 2015 environmental goals three years ahead of schedule, we have set aggressive new goals for 2020 in the areas of greenhouse gas emissions and waste.)
- In January 2014, Biogen Idec was selected as the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights.
- We received accolades for being a great place to work, earning a perfect score of 100 on the Human Rights Campaign Corporate Equality Index, a top-10 placement in the Boston Globe “Top Places to Work,” “Best Places to Work” in Canada, “Company of the Year” in Denmark and “Facility of the Year” in Research Triangle Park (RTP), N.C., where we manufacture many of the therapies we develop for patients.
Philanthropy serves as a centerpiece for our global corporate social responsibility efforts. In May 2014 we announced, in partnership with Swedish Orphan Biovitrum AB, a pledge to donate 1 billion international units of clotting factor therapy over the next 10 years to humanitarian aid programs dedicated to raising the standard of care for people with hemophilia in the developing world.
And through the Biogen Idec Foundation, we operate as a focused philanthropic leader on a global scale. Our efforts are designed to be visible and impactful with a focus on:
- Advancing the goals of transforming science-based education
- Enhancing community-based science programming
- Supporting institutions of higher education
- Providing assistance to community-based organizations
- Offering humanitarian assistance
We accomplish these goals through our global grants programs, providing resources to the communities in which we operate, supporting STEM (Science, Technology, Engineering, Math) education directly and through community funding, and by matching employee contributions — programs that will continue to expand in all of the regions where we operate. We believe that it is our responsibility to ensure the future of innovation in healthcare and the life sciences by helping to support future researchers and clinicians from the youngest learners to those making science a career.
I am proud of our employees and their focus on our purpose and mission — and that together we have taken an approach to citizenship that works to meet the best interests of society and our communities. I invite you to learn more about Biogen Idec and the work we do to help patients around the world, and I am excited to share our fifth annual Corporate Citizenship Report.
George A. Scangos, Ph.D.
Chief Executive Officer